Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2340 - Real World Comparison of Common Patient Reported Symptoms with Health Utility Scores in Cancer Outpatients

Date

10 Sep 2017

Session

Poster display session

Presenters

Mor Moskovits

Citation

Annals of Oncology (2017) 28 (suppl_5): v395-v402. 10.1093/annonc/mdx375

Authors

M. Moskovits1, K. Jao2, C.M. Brown3, S. Su4, H. Naik5, L. Eng3, T. Wang6, Y. Leung7, W. Xu8, G. Liu1, M. Li7, G. Devins7, D. Howell7

Author affiliations

  • 1 Department Of Medical Oncology And Hematology, Princess Margaret Cancer Centre, University of Toronto, M5G2M9 - Toronto/CA
  • 2 Department Of Medical Oncology And Hematology, Hopital Sacre-Coeur, McGill University, Montreal/CA
  • 3 Department Of Medical Oncology And Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto/CA
  • 4 Department Of Biostatistics, Ontario Cancer Institute, Department of Biostatistics, Ontario Cancer Institute, M5N 2P3 - Toronto/CA
  • 5 Department Of Medicine, University of British Columbia, vencouver/CA
  • 6 Faculty Of Pharmacy, University of Toronto, M5N 2P3 - Toronto/CA
  • 7 Palliative Care And Psychosocial Oncology, Princess Margaret Cancer Centre, University of Toronto, M5N 2P3 - Toronto/CA
  • 8 Department Of Biostatistics, Ontario Cancer Institute, Princess Margaret Cancer Centre, University of Toronto, Toronto/CA
More

Resources

Abstract 2340

Background

Health utility scores (HUS), a form of health-related quality of life (HRQoL) assessments useful in economic analyses, such as the EuroQol (EQ-5D) were originally standardized to health state preferences in healthy individuals. To demonstrate clinical appropriateness in cancer patients, we assessed the association of common cancer symptoms with EQ-5D HUS.

Methods

Adult cancer outpatients were surveyed cross-sectionally using the Edmonton Symptom Assessment System (ESAS), the EQ-5D-3L, and clinico-demographic variables. ESAS rated symptoms from 0-10. HUS were derived from the EQ-5D-3L (Canadian conversion). ESAS symptoms were correlated with HUS using Spearman correlation coefficients (R). Multivariable regression analyses identified independent variables associated with HUS.

Results

Of 764 patients across multiple cancers, 27% were palliative at assessment. There were significant correlations between each ESAS symptom score and HUS (p 

Conclusions

HUS is associated with many cancer symptoms, including pain, fatigue, nausea, depression, anxiety, drowsiness, loss of appetite, and shortness of breath. EQ-5D-3L derived HUS have clinical utility. On exploratory analysis, we cannot replace accurately the EQ5D with ESAS, although we can replace two symptom questions within EQ5D with ESAS with high correlation.

Clinical trial identification

Legal entity responsible for the study

Princess Margaret Cancer Centre, UHN, Toronto, Canada

Funding

Cancer Care Ontario

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.